Alnylam Commands Top Trading Rank Despite 55% Volume Slump

Market Snapshot

Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) experienced a notable contraction in trading activity on July 31, 2026, with total transaction volume reaching $0.91 billion. This figure represents a sharp 55.11% decline compared to the previous day’s volume, yet the stock maintained the highest turnover ranking among all equities traded on the market that session. Despite the significant drop in liquidity and the recent volatility, the share price demonstrated resilience, closing with a marginal gain of 0.02%. This near-flat performance stands in stark contrast to the severe intraday plunge witnessed the prior day, suggesting a period of consolidation as the market digested the implications of the company’s latest financial disclosures and the subsequent legal developments. The juxtaposition of the highest trading rank with the lowest volume indicates a highly polarized sentiment, where institutional repositioning or profit-taking may have offset the panic selling observed during the initial market reaction to the guidance cut.

Key Drivers

The primary catalyst for the recent market turbulence was Alnylam’s second-quarter 2026 earnings report and the accompanying downward revision of its full-year financial outlook. On July 30, the company announced that it is lowering its total transthyretin (TTR) product sales guidance for 2026 by approximately $200 million. The revised range for total TTR net product revenues was adjusted from $4.4 billion–$4.7 billion down to $4.2 billion–$4.5 billion. Management attributed this reduction to learnings from the initial phase of the launch in the evolving ATTR-CM (amyloid cardiomyopathy) market. Specifically, the company noted that the growth in second-line volume had normalized after an early period that benefited significantly from pent-up demand from patients who had been waiting for a new therapy. This guidance miss triggered an immediate and severe market reaction, with shares falling as much as $81.25, or 28.35%, in intraday trading on July 30.

While the top-line performance showed robust growth, the details revealed nuances that contributed to investor disappointment. Total net product revenues for the second quarter reached $1.17 billion, a 74% increase from the prior year, driven primarily by the lead drug Amvuttra. Amvuttra generated $1.01 billion in sales, marking the first time the drug exceeded $1 billion in a single quarter. However, this figure missed the Zacks Consensus Estimate of $1.05 billion. Furthermore, adjusted earnings per share of $1.84 also fell short of the consensus estimate of $2.05. The decline in Onpattro sales, which dropped 65% year-over-year to $18.5 million as patients transitioned to Amvuttra, was expected but highlighted the shifting dynamics within the TTR franchise. The combination of missed estimates and reduced future guidance overshadowed the strong quarterly revenue growth, leading to a significant repricing of the stock.

Compounding the negative sentiment from the earnings report was the announcement of multiple securities fraud investigations. On July 31, several prominent law firms, including Kirby McInerney LLP, Glancy Prongay Wolke & Rotter LLP, and the Law Offices of Howard G. Smith, announced they were investigating whether Alnylam and its senior management violated federal securities laws. These investigations were initiated in response to the guidance reduction and the subsequent stock decline. While these announcements are allegations and do not establish wrongdoing, they introduce significant legal and reputational uncertainty. The firms are urging shareholders who lost money on the stock to contact them to discuss potential claims, signaling that a class-action lawsuit may be imminent. This legal overhang adds a layer of risk that may deter some institutional investors and contribute to the cautious trading volume observed on July 31.

Despite the recent headwinds, the long-term outlook for Alnylam remains supported by strong analyst consensus and a robust pipeline. Wall Street maintains a "Moderate Buy" consensus rating with a price target of $445.48, although several brokerages have recently lowered their targets in the wake of the earnings miss. For instance, Truist Financial cut its target from $505 to $410, and JPMorgan reduced its objective from $420 to $400. Nevertheless, the company continues to advance its high-value pipeline, with Phase 2 studies initiated for ALN-6400 in von Willebrand disease and mivelsiran in Down syndrome-associated Alzheimer’s disease. Additionally, the company announced a strategic collaboration with Inceptive Nucleics to integrate AI into its RNAi discovery process and expanded its partnership with Komodo Health to scale commercial intelligence. These strategic moves underscore management's confidence in the underlying science, even as they navigate the immediate challenges posed by the ATTR-CM market normalization and legal scrutiny.